Dovonex

How to order Dovonex

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Dovonex on Prescriptsy

Dovonex is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Dovonex is a prescription-only topical medicine containing calcipotriol, a synthetic vitamin D3 analogue, used for the treatment of plaque psoriasis in the United Kingdom.

Originally developed by LEO Pharma, it is available as a cream, ointment, and scalp solution.

Calcipotriol works by slowing the excessively rapid growth of skin cells in psoriatic plaques and encouraging normal cell maturation, addressing one of the fundamental abnormalities that produces the thick, scaly plaques of psoriasis.

Plaque psoriasis is the most common form of psoriasis, affecting approximately 1.8 million people in the UK.

It presents as well-defined, raised, erythematous patches covered with silvery-white scale, most commonly on the elbows, knees, lower back, and scalp.

The condition is chronic and relapsing, with flare-ups often triggered by stress, infection, skin injury, and certain medications.

Psoriasis is associated with significant physical discomfort and psychological impact, and effective topical treatment is a cornerstone of management for the majority of patients with mild to moderate disease.

This page provides a comprehensive clinical overview of how Dovonex works, who it is suitable for, how to use it correctly, expected timelines, side effects, important safety information, and how to obtain a prescription in the UK.

Important safety information about Dovonex

Before using Dovonex, note the following essential safety points.

• Dovonex is a prescription-only medicine (POM) in the UK. Use it only as directed by your prescriber.
• Do not apply Dovonex to the face. Facial skin is more susceptible to irritation from calcipotriol.
• Do not exceed the maximum weekly dose of 100 g of cream or ointment, or 60 mL of scalp solution. Excessive use can raise blood calcium levels.
• Inform your prescriber if you take vitamin D or calcium supplements, as these may interact with calcipotriol.
• If you develop symptoms of high calcium (persistent nausea, vomiting, excessive thirst, confusion, or muscle weakness), stop using Dovonex and seek medical advice.

Understanding plaque psoriasis and skin cell turnover

In healthy skin, keratinocytes are produced in the basal layer of the epidermis and migrate to the surface over approximately 28 to 30 days, during which time they mature, flatten, and are eventually shed as dead cells.

This orderly process maintains a smooth, intact skin barrier.

In plaque psoriasis, an immune-mediated inflammatory process driven by T-helper 17 (Th17) cells and their associated cytokines dramatically accelerates keratinocyte production.

Skin cells reach the surface in as little as 3 to 5 days without completing normal maturation, resulting in the accumulation of immature, nucleated cells that form the characteristic thick, silvery scale.

This rapid turnover is accompanied by increased blood vessel formation in the dermis (angiogenesis) and infiltration of inflammatory cells including neutrophils, macrophages, and T lymphocytes.

The combination of abnormal cell proliferation, inflammation, and vascular changes produces the raised, red, scaly plaques.

Dovonex targets the proliferative component of this process by restoring a more normal rate and pattern of keratinocyte growth and differentiation.

How Dovonex works: mechanism of action

Calcipotriol is a synthetic analogue of calcitriol (1,25-dihydroxyvitamin D3), the biologically active form of vitamin D produced in the kidneys.

Like calcitriol, calcipotriol binds to the vitamin D receptor (VDR), a nuclear receptor expressed in many cell types including keratinocytes.

On binding, the calcipotriol-VDR complex forms a heterodimer with the retinoid X receptor (RXR) and binds to vitamin D response elements in the DNA, modulating the transcription of genes involved in cell proliferation, differentiation, and immune regulation.

In keratinocytes, calcipotriol inhibits cell proliferation and promotes terminal differentiation, correcting the accelerated and disordered epidermal turnover that characterises psoriasis.

Cells mature in a more orderly fashion and are shed normally, leading to thinning and eventual clearance of the psoriatic plaque.

Calcipotriol also has immunomodulatory effects. It reduces the production of pro-inflammatory cytokines including interleukin-2, interleukin-6, interleukin-8, and interferon gamma by activated T lymphocytes. This contributes to the anti-inflammatory effect observed clinically, with reduction in plaque redness and induration.

Importantly, calcipotriol has approximately 200 times less effect on systemic calcium metabolism than calcitriol, because it is rapidly metabolised in the skin and liver.

This makes it safe for topical use with minimal risk of hypercalcaemia, provided the recommended maximum weekly dose is not exceeded.

Clinical evidence and UK prescribing guidance

Calcipotriol was first licensed in the UK in the early 1990s and has since become one of the most widely prescribed topical treatments for plaque psoriasis.

Randomised controlled trials have demonstrated that twice-daily calcipotriol produces clinically meaningful improvement in approximately 60 to 70% of patients with mild to moderate plaque psoriasis over 8 weeks, with complete or near-complete clearance achieved in around 30% of patients.

Head-to-head trials comparing calcipotriol with potent topical corticosteroids (such as betamethasone valerate) have shown broadly comparable efficacy at 6 to 8 weeks, with the advantage that calcipotriol can be used for longer periods without the risk of skin atrophy, telangiectasia, or striae associated with prolonged corticosteroid use.

NICE Clinical Knowledge Summaries (CKS) on psoriasis recommend topical treatments as first-line therapy for mild to moderate plaque psoriasis.

The options include a potent corticosteroid, a vitamin D analogue (such as calcipotriol), or a combination of both.

Calcipotriol is particularly useful for maintenance therapy and for patients who prefer to avoid or limit corticosteroid exposure.

The British Association of Dermatologists (BAD) guidelines similarly position vitamin D analogues as a first-line topical option alongside corticosteroids.

For scalp psoriasis, calcipotriol scalp solution is recommended as a first-line treatment by NICE, either alone or in combination with a short course of a potent scalp corticosteroid.

Dosage and administration

Apply Dovonex cream or ointment to affected areas once or twice daily, as directed by your prescriber.

Apply a thin, even layer to each plaque and rub in gently. Do not apply to unaffected surrounding skin.

Wash hands thoroughly after application unless the hands are the treatment area.

The scalp solution is applied twice daily (morning and evening) to psoriatic patches on the scalp.

Part the hair to expose the affected areas and apply the solution directly to the plaques using the built-in nozzle.

Do not wash the hair immediately after application; allow the solution to remain in contact with the scalp for optimal absorption.

Emollients should be used regularly alongside Dovonex as part of a comprehensive psoriasis care routine.

Apply emollients at a separate time from Dovonex, ideally at least 30 minutes apart, to prevent the emollient from diluting or washing away the active treatment.

Regular emollient use helps soften scale, reduce itching, and maintain skin hydration.

Improvement is typically noticed within 2 to 4 weeks, with progressive clearing over 6 to 8 weeks.

If there is no meaningful improvement after 8 weeks, your prescriber should reassess the diagnosis and treatment plan.

Unlike corticosteroid-containing preparations, Dovonex does not have a fixed maximum treatment duration and can be continued as maintenance therapy under regular medical review.

Side effects of Dovonex

Common side effects

Local skin reactions at the application site are the most common side effects. These include mild burning or stinging on application, itching (pruritus), redness (erythema), dryness, and peeling.

These reactions are usually mild and temporary, often settling within the first 1 to 2 weeks of treatment as the skin adjusts.

Applying Dovonex to uninvolved skin surrounding plaques increases the likelihood of irritation.

Uncommon side effects

Less common effects include irritant contact dermatitis, worsening of psoriasis at the treatment site, eczematous reactions, and temporary changes in skin pigmentation (darkening or lightening).

Photosensitivity (increased susceptibility to sunburn) has been reported in some patients. If you notice increased sun sensitivity, use sunscreen on exposed areas and avoid prolonged sun exposure.

Rare side effects

Hypercalcaemia is a rare but important systemic side effect that can occur when calcipotriol is used in excess of the recommended maximum weekly dose.

Symptoms include persistent nausea, vomiting, constipation, abdominal pain, excessive thirst, increased urination, muscle weakness, bone pain, fatigue, and confusion.

If you experience these symptoms, stop using Dovonex and contact your GP urgently. Blood calcium levels can be checked with a simple blood test.

Allergic contact dermatitis is rare. If you develop significant worsening of redness, blistering, or swelling at the application site despite continued use, discontinue Dovonex and seek medical advice.

When to seek medical advice

Contact your GP, pharmacist, or NHS 111 if local side effects are persistent, worsening, or significantly uncomfortable. Seek urgent medical advice if you develop signs of hypercalcaemia.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Calcium metabolism

The most important precaution with Dovonex is the risk of hypercalcaemia from excessive use. Strict adherence to the maximum weekly dose is essential.

If you are also using other vitamin D-containing topical treatments (such as Dovobet) or taking oral vitamin D or calcium supplements, inform your prescriber.

The total weekly calcipotriol dose from all sources must remain within safe limits.

Patients with renal impairment are at increased risk because impaired kidney function reduces the ability to regulate calcium levels.

Facial application

Dovonex should not be applied to the face.

Facial skin is thinner and more permeable than body skin, and calcipotriol is more likely to cause irritation, redness, and perioral dermatitis when applied to facial areas.

If psoriasis affects the face, your prescriber can recommend alternative treatments that are safe for facial use, such as mild corticosteroids, calcineurin inhibitors (tacrolimus or pimecrolimus), or emollients alone.

Interaction with other treatments

Salicylic acid inactivates calcipotriol. If you use salicylic acid-containing keratolytics (sometimes used to soften thick psoriatic scale), apply them at a different time of day from Dovonex.

UV light can degrade calcipotriol, so if you are receiving phototherapy, apply Dovonex after your UV session, not before.

Pregnancy and breastfeeding

There is limited information on the use of calcipotriol during pregnancy.

It should be used during pregnancy only if the potential benefit is considered to justify the potential risk.

Calcipotriol is excreted in breast milk in small quantities; breastfeeding women should discuss the risks with their prescriber.

If used during breastfeeding, avoid applying the product to the breast area.

Dovonex compared with other psoriasis treatments

Dovonex occupies a well-established position in the stepwise management of plaque psoriasis.

Compared with potent topical corticosteroids, calcipotriol offers similar long-term efficacy without the risk of skin thinning, making it suitable for extended or maintenance use.

Corticosteroids provide faster initial improvement but carry cumulative risks with prolonged use.

The combination product Dovobet, which pairs calcipotriol with betamethasone, offers faster clearance than either ingredient alone and is often used for acute flares, with Dovonex continuing as maintenance therapy between corticosteroid courses.

Coal tar preparations are effective but cosmetically unappealing and less commonly used today.

Dithranol (anthralin) is a potent antipsoriatic agent but requires careful titration and can stain skin and clothing.

Newer topical agents, including the PDE4 inhibitor roflumilast cream, are becoming available for specific clinical scenarios.

For psoriasis that does not respond adequately to topical treatments, NHS treatment pathways include phototherapy (narrowband UVB), systemic medicines (methotrexate, ciclosporin, acitretin, dimethyl fumarate, apremilast), and biologic therapies.

Referral to a dermatologist is appropriate when topical therapy fails to control the condition adequately.

How to get a Dovonex prescription in the UK

Dovonex is a prescription-only medicine available through the NHS. Your GP can prescribe it following a clinical assessment of your psoriasis type, severity, and distribution.

If your psoriasis is extensive, resistant to topical treatment, or affecting your quality of life, your GP may refer you to a dermatologist for specialist assessment and management.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe Dovonex following a structured online consultation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Dovonex Cream, Summary of Product Characteristics (EMC)
• Calcipotriol, British National Formulary (BNF)
• NICE CKS: Psoriasis
• Psoriasis, NHS
• British Association of Dermatologists, Psoriasis
• MHRA Yellow Card Scheme